Press Releases
FierceBiotech Names Resolvyx Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2008
Resolvyx Pharmaceuticals is "Fierce," on Leading Edge of Biotech
BEDFORD, MA – June 24, 2008 -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. Resolvyx Pharmaceuticals was determined to be one of the "fiercest," proven by their creativity and innovations in the industry.
An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on drug discovery and clinical trials.
John Carroll, Editor of FierceBiotech, said, "With an approach that can be compared to Sirtris, Resolvyx is taking an active ingredient from nature and engineering it into a therapy with a lineup of potential applications. And it has some of the world's top scientists advising it. Resolvyx is off to a fast start on the way to clinical proof-of-concept data."
Resolvyx Pharmaceuticals is discovering and developing novel, small molecule therapies called resolvins to treat inflammatory diseases. Derived from the enzymatic oxidation of omega-3 fatty acids, resolvins are highly potent in preclinical models of multiple human diseases. Resolvyx is developing resolvin-based therapeutics to treat a range of both rare and highly prevalent inflammatory diseases and anticipates advancing their lead drug candidate into clinical trials this year, and a second drug candidate into the clinic early next year.
"FierceBiotech is renowned for its advanced understanding of biotechnology companies and the industry as a whole," said Paul Rubin, M.D., President and Chief Executive Officer of Resolvyx. "Being selected as a member of the 'Fierce 15' is an honor that highlights Resolvyx Pharmaceuticals’s potential to make a significant impact in the biotech market, and our rapid progress in advancing these novel compounds to clinic."
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. The complete list of 'Fierce 15' companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.
About Resolvins
Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an immuno-inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the environmental insult has passed.
Resolvins are attractive drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (like Crohn's disease, psoriasis and rheumatoid arthritis), allergic diseases (like asthma) and chronic inflammatory disease like atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer's disease. Resolvins offer an entirely novel biological approach to treating significant inflammatory diseases, with a decreased potential for immuno-suppression.
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately held biotechnology company dedicated to the development and commercialization of novel therapies to treat inflammatory diseases. The company's key technologies are based on small molecules derived from the enzymatic oxidation of omega-3 fatty acids. These small molecules, called resolvins, have been shown to have significant anti- inflammatory effects in multiple models of human disease processes. Resolvyx's drug R&D programs are focused on developing resolvin-based compounds to treat a range of both rare and highly prevalent inflammatory diseases. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive patent portfolio.
The company's headquarters are in Bedford, Massachusetts. For additional information, please visit http://www.resolvyx.com.
About FierceMarkets
FierceMarkets is a digital business media company serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets publications reach more than 450,000 executives in over 100 countries every business day. Current publications include The Business VoIP Report (http://www.businessvoipreport.com), FierceBioResearcher (http://www.fiercebioresearcher.com), FierceBiotech (http://www.fiercebiotech.com), FierceBroadbandWireless (http://www.fiercebroadbandwireless.com), FierceCIO (http://www.fiercecio.com), Fierce CIO: Tech Watch (http://www.fiercecio.com/techwatch), FierceDeveloper (http://www.fiercedeveloper.com), FierceFinance (http://www.fiercefinance.com), FierceFinanceIT (http://www.fiercefinanceit.com), FierceHealthCare (http://www.fiercehealthcare.com), FierceHealthFinance (http://www.fiercehealthfinance.com), FierceHealthIT (http://www.fiercehealthit.com), FierceIPTV (http://www.fierceiptv.com), FierceMobileContent (http://www.fiercemobilecontent.com), FierceMobileIT (http://www.fiercemovbileit.com), FierceOnlineVideo (http://www.fierceonlinevideo.com), FiercePharma (http:www.fiercepharma.com), FierceSarbox (http://www.fiercesarbox.com), FierceTelecom (http://www.fiercetelecom.com), FierceVaccines (http://www.fiercevaccines.com), FierceVoIP (http://www.fiercevoip.com), FierceWireless (http://www.fiercewireless.com), and FierceWireless: Europe (http://www.fiercewireless.com/europe).